Background. Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients. The recurrent and protracted use of antiviral drugs with eventual emergence of drug resistance represents a significant constraint to therapy. Although adoptive T-cell therapy has been successfully used in hematopoietic stem cell transplant recipients, its extension to the SOT setting poses a considerable challenge because of the inhibitory effects of immunosuppressive drugs on the virus-specific T-cell response in vivo and the perceived risk of graft rejection.
Clinical management of cytomegalovirus (CMV) infection in solid organ transplant (SOT) recipients remains a major challenge. The incidence of early CMV-associated complications in SOT recipients has decreased significantly since the advent of virostatic therapy based on ganciclovir [1] . The inhibition of viral reactivation by either the prophylactic or preemptive administration of ganciclovir has therefore become critical in the prevention of CMV-associated disease. However, late CMV reactivation can be more problematic to manage, especially in patients who are unable to reconstitute antiviral T-cell immunity [2] . Furthermore, the emergence of ganciclovir-resistant CMV reactivation or disease poses major difficulties in clinical management, with significant morbidity and mortality due to drug-associated toxicity, immunomodulatory impact, and allograft loss [3] .
Alternative safe and effective therapeutic options for ganciclovir-resistant CMV are lacking. Antiviral management strategies using foscarnet or cidofovir are associated with nephrotoxicity and require intravenous administration and hospitalization. Genes conferring resistance to ganciclovir are also associated with resistance to foscarnet and cidofovir. Newer antiviral therapeutics, such as maribavir and letermovir, may offer alternatives for the treatment of CMV, with the potential for reduced adverse effects [4, 5] . Viral control can be improved by reducing immunosuppression, but this increases the risk of graft rejection. During the last decade, a number of immune-based diagnostic tests have been developed that can help to identify patients at increased risk of early or late CMV-associated complications [6] . These studies have clearly shown that the reconstitution of antiviral T-cell immunity is absolutely critical in protecting SOT recipients from CMV infection or reactivation [7] [8] [9] .
The reconstitution of CMV immunity through the administration of CMV-specific T cells offers an attractive option to enhance the control of CMV in SOT recipients. This approach has been used very effectively to treat CMV-associated complications in hematopoietic stem cell transplant (HSCT) recipients. However, this is typically dependent on the use of HSCT donor-derived material to generate CMV-specific cell therapy, whereas in the context of SOT recipients, autologous immune cells from heavily immunosuppressed individuals are required to generate an effective T-cell therapy. Although it showed some promising results with an autologous CMV-specific T-cell therapy in an SOT recipient, a previous case study also raised potential safety concerns [10] . As a consequence, the development of this approach has been limited owing to the perceived difficulties in generating T cells from highly immunosuppressed SOT recipients, and the potential risks associated with graft rejection after T-cell administration.
Despite these concerns, earlier case reports demonstrated the use of autologous T-cell therapies for CMV disease in 2 transplant recipients with no evident adverse effects [11, 12] As a consequence of these promising results, we initiated a formal phase I study to assess the safety of autologous therapy in a larger cohort of lung, heart, and kidney transplant recipients with CMV-associated complications. We demonstrate here the capacity to generate CMV-specific T cells from the majority of recruited SOT recipients despite these underlying complications. After adoptive immunotherapy, we detected only grade 1 and 2 adverse events potentially associated with T-cell infusion, and we saw no evidence for any impact on graft function or survival. More importantly, the majority of the patients showed resolution of clinical symptoms, which was coincident with antiviral T-cell reconstitution in four of the treated patients.
MATERIALS AND METHODS

Patient Recruitment and Study Design
This single-arm open-label phase I study was performed according to the principles of the Declaration of Helsinki and approved by the ethics committees of QIMR Berghofer Medical Research Institute, The Prince Charles Hospital, and the Royal Adelaide Hospital. It was registered under the Australian New Zealand Clinical Trial Registry (ACTRN12613000981729). Patients were deemed eligible for the study if they met ≥1 of the following criteria: (1) CMV reactivation or disease (as defined by histology) after successful initial therapy, (2) persistent CMV disease (ie, no response to 2 weeks of salvage foscarnet or other second-line antiviral agent), (3) persistent CMV replication (>6 weeks by polymerase chain reaction analysis) despite appropriate antiviral therapy, and (4) any CMV reactivation or disease where antiviral therapy is contraindicated owing to intolerance or end-organ limitation (eg, renal impairment or marrow dysfunction). CMV disease was defined as organ dysfunction due to CMV infection and/or evidence of tissue invasive viral infection. Antiviral drug therapy was administered according to institutional guidelines. Standard prophylaxis for lung transplant recipients was valganciclovir until 9 months after transplantation. CMV immunoglobulin G and lifelong valganciclovir was administered to D+R− (donor CMV seropositive, recipient CMV seronegative) lung transplant recipients. Standard prophylaxis for renal transplant recipients included 3 months of valganciclovir for D+R+ and D−R+ patients, 6 months of valganciclovir for D+R− patients, and no treatment for D−R− patients. Standard prophylaxis for heart transplant recipients was valganciclovir until 6 months after transplant for D+R+ patients, valganciclovir until 12 months for D+R− patients, and valacyclovir for D−R− patients. Patients received up to 6 doses of in vitro-expanded T cells at a dose of 1-2 × 10 7 /m 2 body surface area every 2 weeks.
Each participant was monitored for safety, clinical symptoms, viral load, and immune reconstitution for 28 weeks after the completion of adoptive T-cell therapy. Viral load monitoring was undertaken using the Cobas TaqMan polymerase chain reaction assay (Roche Molecular Diagnostics), as described elsewhere [13] . The lower limit of detection for this assay is 150 copies/mL.
Manufacture and Adoptive Transfer of CMV-specific T Cells
To manufacture the CMV-specific T-cell therapy for each patient, peripheral blood mononuclear cells (PBMCs) were stimulated with a clinical-grade custom peptide pool (JPT Technologies), which includes predefined HLA class I-and class II-restricted peptide epitopes from pp65, pp50, IE-1, gH, and gB (Supplementary Table 1 ) [14] [15] [16] . These cells were cultured in Grex-10 culture flasks (Wilson Wolf) at a starting cell density of 2-5 × 10 6 /cm 2 . The cultures were supplemented with recombinant interleukin 21 (40 ng/mL) on day 0 and recombinant interleukin 2 (120 IU/mL) on day 2 and every 3 days thereafter. On day 14, expanded T cells were harvested and frozen in 1-mL single-dose aliquots in Albumex 4 (CSL Behring) containing 10% dimethyl sulfoxide (WAK-Chemie Medical).
A dedicated good manufacturing practice-accredited cell therapy manufacturing facility (Q-Gen Cell Therapeutics) was used for T-cell therapy manufacturing and storage. At the completion of in vitro culture, T cells were phenotypically and functionally characterized using Multitest 6-Colour TBNK Reagent (BD Biosciences) and intracellular cytokine staining (detailed below). Microbiological testing was performed as recommended in the British Pharmacopoeia 2015 (Appendices XVIE and XVIA) in all T-cell products, for the presence or absence of microbiological contamination (fungal and bacterial, including Mycoplasma) and endotoxin (<3 endotoxin units/mL). For adoptive transfer, T cells were thawed into 19 mL of clinical-grade normal saline and infused intravenously over a period of 5-10 minutes.
Intracellular Cytokine Analysis of CMV-specific T Cells
To characterize the T-cell therapy and PBMCs isolated from follow-up blood samples, cells were stimulated with CMV peptide epitopes and assessed for the expression of interferon (IFN) γ, tumor necrosis factor (TNF), and interleukin 2 and the mobilization of CD107, using an intracellular cytokine assay, as described elsewhere [17] . Cells were acquired using a BD LSR Fortessa cell analyzer with FACSDiva software (BD Biosciences). Postacquisition and Boolean analyses were performed using FlowJo software version 10 (FlowJo).
RESULTS
Patient Characteristics and T-cell Therapy Manufacturing
The primary objective of this study was to assess the safety of autologous T-cell therapy in SOT recipients with CMV-associated complications. The clinical characteristics of the participants included in this study are provided in Table 1 . CMV reactivation was managed in patients 1553PAH06, 1553PAH08, and 1553PAH09 by a combination of antiviral therapy and reduction in immunosuppression before enrollment in the clinical trial. In total, 21 SOT recipients (13 renal, 8 lung, and 1 heart transplant recipient) were included in the study. Two of the lung transplant recipients included in the follow-up analyses had been previously treated under the Special Access Scheme of the Therapeutic Goods Administration [11, 12] . Of the 21 SOT recipients analyzed, 13 were allocated to intervention and received a maximum of 6 doses of adoptive T-cell therapy, and 1 discontinued therapy after a single dose, with no immune monitoring. Of the remaining 8 patients, 7 did not receive adoptive T-cell therapy owing to improvement in their clinical status, and we failed to manufacture therapy for 1 patient. CMV-specific T cells were successfully expanded from 20 of the 21 patients, and their antigen specificity was assessed by means of intracellular IFN-γ analysis ( Table 2) . The CMV peptide pool-expanded cells were predominantly CD3 + CD8 + T cells ( Figure 1A) , with a median specificity of 51.2% ( Figure 1B) . The frequency of IFN-γ-producing CD8 + T cells did not differ significantly between kidney and lung/ heart transplant recipients ( Figure 1C ) or between pretransplant CMV-seropositive and CMV-seronegative individuals ( Figure 1D) . A marked improvement in the polyfunctionality of the CMV-specific T cells was observed after in vitro expansion, with an increase in the proportion of cells capable of producing IFN-γ, TNF, and CD107a ( Figure 1E ). T cells generated from the majority of the patients showed reactivity against multiple peptide epitopes encoded by multiple CMV antigens ( Table 2) .
Clinical Outcomes After Adoptive Immunotherapy
None of the patients who received adoptive CMV-specific T-cell therapy showed treatment-related grade 3, 4, or 5 adverse events (Table 3 and Supplementary Table 2 ). All adverse events that were deemed at least possibly attributable to T-cell infusion were grade 1 or 2, and these included fatigue and malaise. Importantly, no adverse events associated with a change in the graft status were detected. Clinical follow-up of patients allocated to T-cell therapy intervention indicated that 11 of the 13 showed objective improvement in their symptoms. These improvements included reduction or resolution of CMV reactivation and/or disease and improved response to antiviral drug therapy. The median peak viral load before adoptive T-cell therapy in the 11 patients with a clinical response was 3.2 × 10 4 CMV copies/mL of blood (range, 1.4 × 10 3 to 3.44 × 10 5 copies/mL).
After adoptive immunotherapy, the median viral load dropped to 1.2 × 10 3 CMV copies/mL of blood (range 0-7.9 × 10 3 copies/mL; Table 4 ). Furthermore, many of these patients showed resolution of CMV disease symptoms (Table 4 ). More importantly, after the completion of adoptive T-cell therapy, the use of b The KAR peptide was added to the CMV peptide pool for stimulation.
c HLA-specific peptide pools were generated to manufacture T cells for these patients.
antiviral drug therapy was either completely stopped (in 5 of 11 patients) or significantly reduced (in 6 of 11; Table 4 ).
Virological and Immunological Monitoring After T-cell Therapy
To assess the impact of adoptive T-cell therapy on CMVspecific T-cell immune reconstitution, we conducted a longitudinal intracellular cytokine analysis after immunotherapy, overlaying this analysis with virological monitoring in each patient. Representative data from 8 patients, including 7 who showed an objective response to adoptive immunotherapy, are shown in Figure 2 . This analysis revealed evidence of immunological reconstitution after therapy in association with control of viremia. This is best exemplified in patient 1553PAH08, whose proportion of IFN-γ-producing CMV-specific T cells increased from 0.03% before the first infusion to 9.3% at the end of the follow-up period, with a concordant reduction in viral load and cessation of antiviral drug therapy (Figure 2A) . A similar improvement in peripheral T-cell immunity after the commencement of T-cell infusions was also evident in other patients, including patients 1553PAH09, 1553PCH02, and 1553PCH04 ( Figure 2A ). It is important to note that immune reconstitution in these patients was observed despite the continuation of immunosuppressive therapies prescribed before adoptive T-cell therapy (Table 1) . Coincident with immune reconstitution, we also observed improvement in the functional quality of CMV-specific T-cell responses, characterized by an increased proportion of T cells coexpressing IFN-γ, TNF, and CD107 ( Figure 2B ). In contrast, patient 1553RAH01, who did not respond clinically to therapy, showed no evidence of immunological reconstitution after therapy. Patient 1553PCH01 experienced a decline in CMV-specific T-cell immunity, coincident with contracting a secondary infection that caused bilateral bronchopneumonia. Follow-up immunological analysis was not possible for patient 1553PCH03, who died soon after the commencement of therapy owing to complications related to CMV infection. Interestingly, although patients 1553PAH06 and 1553PCH05 showed clinical improvement, there was no change in the frequency of CMV-specific T cells in their peripheral blood after adoptive T-cell therapy.
DISCUSSION
In this study we describe the first formal evaluation of autologous CMV-specific T-cell therapy in SOT recipients. In a cohort of patients recruited because of evidence of drug resistance or intolerance, or persistent viral reactivation or disease, we demonstrated no evidence of severe adverse events or any negative impact on the graft after T-cell administration. Although this study was not designed to access efficacy, we saw evidence of viral control after T-cell therapy in the majority of treated patients. This provides a platform to evaluate the potential efficacy of T-cell therapy in a larger cohort of SOT recipients, with the inclusion of a control arm.
The therapeutic efficacy of donor-derived CMV-specific T-cell therapy in HSCT recipients has provided clear evidence of the potential therapeutic benefits of adoptive cell therapy in both preventing and treating viral disease in transplant recipients [18, 19] . In contrast with CMV-specific T cells generated from healthy CMV-seropositive individuals for administration in HSCT recipients, which has now been administered to >100 patients [20, 21] , autologous CMV-specific immunotherapy in SOT recipients is dependent on the capacity to generate CMVspecific T cells from immunosuppressed individuals. However, case reports in both SOT and HSCT recipients have shown its potential efficacy [10] [11] [12] [13] . Consistent with these previous observations, we were able to generate CMV-specific T cells from 20 of the 21 patients for whom T-cell manufacture was attempted in the current study.
Our observations indicate that despite the heavy immunosuppressive regimens used to prevent graft rejection, the majority of these individuals were able to prime a CMV-specific T-cell response, and, in some cases, patients had a high precursor frequency in their PBMCs before T-cell expansion. We did note functional defects in the CMV-specific T cells in the peripheral blood of SOT recipients, as reported elsewhere [22] , characterized by a reduced capacity to express TNF and IFN-γ, which could potentially mediate increased sensitivity to viral reactivation. Importantly, and probably owing to the removal of these cells from the immunosuppressive environment, this phenotype could be reversed after in vitro stimulation, with the majority of expanded CMV-specific T cells coexpressing CD107a, TNF, and IFN-γ.
Both virological and immunological monitoring provided evidence of the potential benefit of immunological reconstitution after adoptive immunotherapy for viral control in SOT recipients. Although the study was not designed to assess efficacy, and in some patients the changes were transient, there was evidence in multiple patients that immune reconstitution coincided with reduction in or resolution of viral reactivation. This is particularly important for the SOT recipients in whom drug resistance had developed or who had either ongoing or a history of CMV-associated end-organ disease. We also showed that adoptive T-cell therapy can be safely used, concurrently with immunosuppressive therapies, to prevent CMV-associated complications in patients who are unable to tolerate standard antiviral drug therapy.
In summary, although efficacy needs to be confirmed in controlled trials, this prospective, multicenter, open-label study has confirmed the feasibility and safety of CMV-targeted autologous adoptive T-cell therapy in SOT recipients. It therefore provides an important platform for subsequent controlled studies and for the future application of adoptive T-cell therapy in SOT recipients, especially in a setting where no appropriate treatment options are available.
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